(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for CPHD
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.68
Shares 73.48M
Beta     -
Inst. own 91%

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -6.88% -9.01%
Operating margin -3.61% -5.73%
EBITD margin - 1.59%
Return on average assets -5.18% -6.03%
Return on average equity -11.54% -13.40%
Employees 1,700 -
CDP Score - -


904 E Caribbean Dr
SUNNYVALE, CA 94089-1189
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.